文献速递血栓与止血

慢性肾脏病中的抗凝治疗:现状与未来展望

Anticoagulation in chronic kidney disease: current status and future perspectives.
PubMed 文献 · J Thromb Haemost · 2023-09-29

慢性肾脏病(CKD)在全球范围内诊断日益增多,常合并其他疾病而进一步升高血栓与出血风险。口服抗凝可降低房颤患者缺血性卒中与系统性栓塞发生率,并降低静脉血栓栓塞疾病的发病率与死亡率。但CKD患者因出血与血栓栓塞并发症之间的脆弱平衡,这些获益尚未明确实现。本综述审视CKD抗凝使用现状,并提出实用建议以辅助CKD合并房颤和静脉血栓栓塞患者安全抗凝的决策。

要点

  • CKD患者血栓与出血风险均升高,口服抗凝获益与风险平衡尚不明确。
  • 口服抗凝可降低房颤患者缺血性卒中与系统性栓塞发生率。
  • 口服抗凝可降低静脉血栓栓塞疾病的发病率与死亡率。

核心结论

  • CKD患者因出血与血栓栓塞并发症之间的脆弱平衡,口服抗凝的获益尚未明确实现,本综述提出实用建议以辅助安全抗凝决策。

研究设计与样本

  • 综述,审视CKD抗凝使用现状并提出实用建议,原文未报告检索范围。

主要发现

  • CKD在全球诊断日益增多,常合并其他疾病而进一步升高血栓与出血风险。
  • 口服抗凝可降低房颤患者缺血性卒中与系统性栓塞发生率,并降低静脉血栓栓塞疾病的发病率与死亡率。
  • CKD患者因出血与血栓栓塞并发症之间的脆弱平衡,上述获益尚未明确实现。

临床怎么用

  • 作者提出实用建议以辅助CKD合并房颤和静脉血栓栓塞患者安全抗凝的决策过程。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic kidney disease (CKD) is being diagnosed increasingly worldwide. It is often identified in individuals with comorbidities, which may increase the already heightened risk of thrombosis and hemorrhage associated with CKD. Oral anticoagulation is an effective means of reducing rates of ischemic stroke and systemic embolism in patients with atrial fibrillation and minimizes the morbidity and mortality caused by venous thromboembolic disease. Despite the proven benefits in the majority of patients, these have not been so clearly realized in patients with CKD due to the precarious balance between bleeding and thromboembolic complications. In this review, the current status of anticoagulant utilization in CKD is examined, and some practical recommendations are put forward to assist in the decision-making process of safely anticoagulating patients with CKD diagnosed with atrial fibrillation and venous thromboembolism.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Jones A, Swan D, Lisman T, et al. Anticoagulation in chronic kidney disease: current status and future perspectives. J Thromb Haemost. 2023. PMID: 37778512. doi:10.1016/j.jtha.2023.09.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。